Adherence enhancers in pill-related clinical trials: a health behavior in cancer prevention model-based approach.
Preventing non-adherence and treating adherence failure are important to consider in designing community-based clinical trials. The approach and methods for managing adherence are vital. This paper describes a practical and theoretically-based strategy for managing adherence in a small cancer prevention trial with subjects (n = 40) taking a non-steroidal anti-inflammatory drug, piroxicam. Average daily pill intake adherence was exceptionally high (97.4%) as measured by self-report calendar. Thus, the generalized adherence enhancement approach used in this study may have been a related factor, although statistical model-testing was not possible in this small trial. The generalized intervention took into account factors such as the potential barriers and benefits of being in the study, self-efficacy and satisfaction with the participant/staff relationship. These and other theoretical variables were incorporated into an overall adherence strategy that is discussed.
Atwood
J R
JR
Giordano
L
L
Vargas
P
P
Blackwell
G G
GG
Earnest
D L
DL
Meyskens
F
F
Alberts
D
D
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000517:prevention & control*; D005260:Female; D015438:Health Behavior; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D008960:Models, Psychological; D010349:Patient Compliance; D010353:Patient Education as Topic; D010894:Piroxicam / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam